CARDINAL HEALTH INC
CAHAPI behind this page
CAH Q4 2025 request
Playground key active
/api/financials?ticker=CAH&year=2025&quarter=4
Pick an endpoint and run the request.Income Statement
| Metric | Q4 2025 | Q4 2024 | YoY |
|---|---|---|---|
| Revenue | 60,159 | 59,867 | +0.5% |
Show Business Segments breakouts |
|||
| All Other Segments · at-Home Solutions | 1,089 | 733 | +48.6% |
| All Other Segments · Operating Segments | 1,609 | 1,172 | +37.3% |
| All Other Segments · OptiFreight Logistics | 90 | 76 | +18.4% |
| GMPD · Operating Segments | 3,199 | 3,109 | +2.9% |
| Pharmaceutical and Specialty Solutions · Operating Segments | 55,372 | 55,607 | -0.4% |
Show Geography breakouts |
|||
| Non Us | 434 | 440 | -1.4% |
| US | 59,746 | 59,448 | +0.5% |
Show — breakouts |
|||
| Revenue | 430 | 363 | +18.5% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | -21 | -21 | 0.0% |
| Operating Segments | 60,180 | 59,888 | +0.5% |
| Cost of Revenue | 57,957 | 57,985 | -0.0% |
| Gross Profit | 2,202 | 1,882 | +17.0% |
| Selling, General & Administrative | 1,484 | 1,277 | +16.2% |
| Restructuring Charges | 27 | 69 | -60.9% |
| Amortizationandotheracquisitionrelatedcosts | 133 | 77 | +72.7% |
| Gain Loss On Sales Of Assets And Asset Impairment Charges | 33 | 8 | +312.5% |
| Gain Loss Related To Litigation Settlement | -9 | 50 | -118.0% |
| Operating Income | 428 | 401 | +6.7% |
Show Business Segments breakouts |
|||
| All Other Segments · Operating Segments | 160 | 111 | +44.1% |
| GMPD · Operating Segments | 70 | 47 | +48.9% |
| Pharmaceutical and Specialty Solutions · Operating Segments | 535 | 482 | +11.0% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | -337 | -239 | -41.0% |
| Operating Segments | 765 | 640 | +19.5% |
| Other Non-Operating Income (Expense) | -30 | 1 | -3100.0% |
| Interest Expense | 74 | 9 | +722.2% |
| Income Before Taxes | 384 | 391 | -1.8% |
| Income Tax Expense (Benefit) | 141 | 158 | -10.8% |
| Net Income | 243 | 233 | +4.3% |
Show Equity Components breakouts |
|||
| Noncontrolling Interest | 4 | -2 | +300.0% |
| Net Income Loss Attributable To Noncontrolling Interest | -4 | 2 | -300.0% |
| Net Income | 239 | 235 | +1.7% |
| Wtd Avg Shares (Basic) | -1 | 0 | — |
| Wtd Avg Shares (Diluted) | -1 | 0 | — |
| Comprehensive Income | 260 | 228 | +14.0% |
| Other Comprehensive Income | 21 | -7 | +400.0% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | 21 | -7 | +400.0% |
Balance Sheet
| Metric | Q4 2025 | Q4 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 3,874 | 5,133 | -24.5% |
| Receivables Net Current | 13,242 | 12,084 | +9.6% |
| Inventory | 16,831 | 14,957 | +12.5% |
| Other Assets Current | 2,414 | 2,663 | -9.4% |
| Assets Of Disposal Group Including Discontinued Operation | 12 | 47 | -74.5% |
| Total Current Assets | 36,373 | 34,884 | +4.3% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 2,858 | 2,529 | +13.0% |
Show Geography breakouts |
|||
| Non Us | 436 | 423 | +3.1% |
| US | 2,422 | 2,106 | +15.0% |
| Other Non-Current Assets | 1,714 | 1,258 | +36.2% |
| Total Assets | 53,122 | 45,121 | +17.7% |
Show Business Segments breakouts |
|||
| All Other Segments · Operating Segments | 4,045 | 2,606 | +55.2% |
| GMPD · Operating Segments | 6,889 | 7,047 | -2.2% |
| Pharmaceutical and Specialty Solutions · Operating Segments | 37,313 | 29,149 | +28.0% |
Show Consolidated Entities breakouts |
|||
| Variable Interest Entity Primary Beneficiary | 601 | — | — |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | 4,875 | 6,319 | -22.9% |
| Operating Lease Right-of-Use Assets | 758 | 475 | +59.6% |
| Goodwill | 9,691 | 4,725 | +105.1% |
Show Business Segments breakouts |
|||
| All Other Segments | 1,748 | 1,170 | +49.4% |
| Pharmaceutical and Specialty Solutions | 7,943 | 3,555 | +123.4% |
Show Business Acquisition breakouts |
|||
| ADS | 578 | — | — |
| GIA | 3,124 | — | — |
| ION | 910 | — | — |
| Specialty Networks | 784 | — | — |
| Urology America | 307 | — | — |
| Intangible Assets | 2,473 | 1,713 | +44.4% |
Show Business Acquisition breakouts |
|||
| ADS · Customer Related Intangible Assets | 472 | — | — |
| ADS · Trademarks, trade names, and patents | 28 | — | — |
| GIA · Noncompete Agreements | 23 | — | — |
| GIA · Trademarks, trade names, and patents | 200 | — | — |
| ION · Customer Related Intangible Assets | 226 | — | — |
| ION · Trademarks, trade names, and patents | 73 | — | — |
| Specialty Networks · Customer Related Intangible Assets | 480 | — | — |
| Specialty Networks · Developed Technology Rights | 20 | — | — |
| Specialty Networks · Noncompete Agreements | 5 | — | — |
| Specialty Networks · Trademarks, trade names, and patents | 15 | — | — |
| Urology America · Trademarks, trade names, and patents | 33 | — | — |
Show Finite Lived Intangible Assets By Major Class breakouts |
|||
| Customer Related Intangible Assets | 1,237 | 1,197 | +3.3% |
| Developed Technology Rights | 304 | 363 | -16.3% |
| Noncompete Agreements | 51 | — | — |
| Trademarks, trade names, and patents | 881 | 153 | +475.8% |
| Other Assets | |||
| Intangible Assets Net Including Goodwill | 12,177 | 6,450 | +88.8% |
| Current Liabilities | |||
| Accounts Payable | 34,713 | 31,759 | +9.3% |
| Long Term Debt And Capital Lease Obligations Current | 550 | 434 | +26.7% |
| Other Accrued Liabilities Current | 3,634 | 3,447 | +5.4% |
| Total Current Liabilities | 38,897 | 35,640 | +9.1% |
| Non-Current Liabilities | |||
| Deferred Tax And Other Liabilities Noncurrent | 8,882 | 8,035 | +10.5% |
| Operating Lease Liabilities | 654 | 400 | +63.5% |
| Total Liabilities (Q) | — | — | — |
Show Consolidated Entities breakouts |
|||
| Variable Interest Entity Primary Beneficiary | 187 | — | — |
| Other Liabilities | |||
| Long Term Debt And Capital Lease Obligations | 7,977 | 4,658 | +71.3% |
| Stockholders' Equity | |||
| Common Stock | 2,956 | 2,917 | +1.3% |
| Retained Earnings | 783 | -286 | +373.8% |
| Treasury Stock Value | -6,365 | -5,677 | -12.1% |
| Accumulated Other Comprehensive Income | -155 | -167 | +7.2% |
| Total Stockholders' Equity | -2,781 | -3,213 | +13.4% |
| Minority Interest | 147 | 1 | +14600.0% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | -2,634 | -3,212 | +18.0% |
Show Equity Components breakouts |
|||
| Accumulated Foreign Currency Adjustment Including Portion Attributable To Noncontrolling Interest | -141 | -138 | -2.2% |
| Accumulated Gain Loss Net Cash Flow Hedge Noncontrolling Interest | -14 | -29 | +51.7% |
| Accumulated Other Comprehensive Income | -155 | -167 | +7.2% |
| Aoci Including Portion Attributable To Noncontrolling Interest | -155 | — | — |
| Common Stock | 2,956 | 2,917 | +1.3% |
| Noncontrolling Interest | 147 | 1 | +14600.0% |
| Retained Earnings | 783 | -286 | +373.8% |
| Total Liabilities & Equity | 53,122 | 45,121 | +17.7% |
Cash Flow Statement
| Metric | YTD Q4 2025 | YTD Q4 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation & Amortization | 209 | 186 | +12.4% |
| Stock-Based Compensation | 153 | 33 | +363.6% |
| Provision For Doubtful Accounts | 12 | 8 | +50.0% |
| Increase Decrease In Receivables | -466 | -773 | +39.7% |
| Change in Inventory | -607 | 2,373 | -125.6% |
| Change in Accounts Payable | 1,778 | -294 | +704.8% |
| Increase Decrease In Other Operating Capital Net | -72 | 410 | -117.6% |
| Net Cash from Operations | 1,527 | 2,082 | -26.7% |
| Investing Activities | |||
| Capital Expenditures | -232 | -193 | -20.2% |
| Payments To Acquire Businesses Net Of Cash Acquired | -1,395 | 2 | -69850.0% |
| Proceeds From Hedge Investing Activities | 0 | 6 | -100.0% |
| Net Cash from Investing | -1,631 | 166 | -1082.5% |
| Financing Activities | |||
| Repayments Of Long Term Debt | -11 | -760 | +98.6% |
| Netproceedstaxwithholdingsfromsharebasedcompensation | -1 | 23 | -104.3% |
| Payments Of Dividends Common Stock | -120 | -122 | +1.6% |
| Share Repurchases | 0 | 0 | — |
| Net Cash from Financing | 656 | -859 | +176.4% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | -4 | -2 | -100.0% |
| Net Change in Cash | 548 | 1,387 | -60.5% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 3,874 | 5,133 | -24.5% |
Values in millions USD. Source: SEC EDGAR 10-K filing.